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Highlights 
 Mathematically modeling syn spread along fiber tracts recreates inclusions patterns 
 Modeled retrograde (post-to-presynaptic) spread best recreates early inclusions patterns 
 Modeled anterograde (pre-to-postsynaptic) spread better fits later inclusions pattern 
 Overall results indicate a potential directional switch in syn spread over time 
 All above results are consistent across multiple, independently collected, datasets 
 
 
Abstract 
 
In Parkinson’s disease, some of the first alpha-synuclein aggregates appear in the olfactory 
system and the dorsal motor nucleus of the vagus nerve before spreading to connected brain 
regions. We previously demonstrated that injection of alpha-synuclein fibrils unilaterally into the 
olfactory bulb of wild type mice leads to widespread synucleinopathy in brain regions directly 
and indirectly connected to the injection site, consistently, over the course of periods longer than 
6 months. Our previously reported observations support the idea that alpha-synuclein inclusions 
propagates between brain region through neuronal networks. In the present study, we further 
defined the pattern of propagation of alpha-synuclein inclusions and developed a mathematical 
model based on known mouse brain connectivity. Using this model, we first predicted the pattern 
of alpha-synuclein inclusions propagation following an injection of fibrils into the olfactory bulb. 
We then analyzed the fitting of these predictions to our published histological data. Our results 
demonstrate that the pattern of propagation we observed in vivo is consistent with axonal 
transport of alpha-synuclein aggregate seeds, followed by transsynaptic transmission. By 
contrast, simple diffusion of alpha-synuclein fits very poorly our in vivo data. We also found that 
the spread of alpha-synuclein inclusions appeared to primarily follow neural connections 
retrogradely until 9 months after injection into the olfactory bulb. Thereafter, the pattern of 
spreading was consistent with anterograde propagation mathematical models. Finally, we applied 
our mathematical model to a different, previously published, dataset involving alpha-synuclein 
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fibril injections into the striatum, instead of the olfactory bulb. We found that the mathematical 
model accurately predicts the reported progressive increase in alpha-synuclein neuropathology 
also in that paradigm. In conclusion, our findings support that the progressive spread of alpha-
synuclein inclusions after injection of protein fibrils follows neural networks in the mouse 
connectome.  
 
Introduction 
Parkinson’s disease is characterized neuropathologically both by death of substantia nigra 
dopamine neurons and the progressive accumulation of pathological inclusions in widespread 
parts of the nervous system [19]. These inclusions, named Lewy bodies and Lewy neurites, are 
mainly composed of misfolded alpha-synuclein (syn) [18; 19] and they engage an increasing 
number of brain regions as the disease progresses over several years. This spreading of Lewy 
pathology in the brain follows a stereotypical pattern and has been suggested to first start in the 
olfactory system and the dorsal motor nucleus of the vagus [4; 5; 6; 7; 8; 15]. The brain regions 
that sequentially develop Lewy pathology in PD are all interconnected, an observation that 
provided some of the scientific premise for the hypothesis that syn aggregates can propagate 
from one neuron to another via neural connections [1; 4; 10; 21].  
Extensive work using in vitro models has subsequently demonstrated that misfolded syn 
can act as a template and impose its aberrant conformation to native syn, and that the seeds of 
misfolded syn can be released and taken up by neighboring cells that in turn develop syn 
inclusions [11; 20; 40; 44]. Thus, misfolded syn itself could be a vector of propagation and 
could underlie a propagation of synucleinopathy between brain regions in humans [11; 37]. To 
address this hypothesis, several groups have tested the seeding and prion-like spreading of 
pathological syn in vivo [13; 14; 37]. Intracerebral or peripheral injection of recombinant syn 
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fibrils or syn aggregates derived from brain lysates from post-mortem patients with 
synucleinopathy can induce syn aggregation in both animals overexpressing syn and in wild 
type animals [11; 14; 24; 32; 37].  
 Several previously published studies have focused on defining the development of 
abnormal syn inclusions following injections into the striatum or in the substantia nigra, which 
exhibit synucleinopathy only in advanced PD. By contrast, recent reports from our group have 
focused on triggering synucleinopathy in the olfactory bulb because it is believed to be one of the 
first brain regions affected in PD [34; 35; 36; 37]. By unilateral stereotaxic injection of 
recombinant syn fibrils into the olfactory bulb of wild type mice, we have demonstrated syn 
aggregation is initially triggered at the site of injection and then it progressively spreads 
sequentially to interconnected brain regions [34; 36]. Our published observations strongly 
suggest propagation via a neuronal network, but they do not completely rule out other spreading 
routes such as local diffusion, or migration of glia containing seeds [33]. Indeed, some reviews 
of the literature to date on syn pathology spread question whether the propagate via neural 
connectivity [40] and suggest that given inconsistencies in the transsynaptic spread literature, 
perhaps cell-type specific explanations might provide a better explanation [42] for observed 
pathology proliferation patterns. 
 To further define the anatomical patterns and dynamics of the spread of syn inclusions, 
and thereby gain greater insight into the role of neural connections, here we reanalyze our own 
data with a specific focus on network transmission of inclusions. For this purpose, we use our 
recently developed mathematical model called Directional Network Transmission (DNT) [26; 
27], which we have previously demonstrated can predict tau pathology transmission in the mouse 
brain, but does not well represent a progression. In turn, this model was based on our original 
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Network Diffusion model of human degenerative progression [30; 31], which was successful in 
recapitulating the spatiotemporal pattern of atrophy in human dementia. These mathematical 
models provide a useful new way of testing hypotheses regarding network transmission since 
they do not rely on correlative evidence from isolated regions or fiber projections, but can be 
applied to the entire brain connectome at once. This addresses a gap in the current research 
regarding the relationship between neural connectivity and syn spread, as there is presently a 
lack of studies elucidating the relationship between the whole brain connectome and syn 
inclusions patterns [42]. In addition, while both anterograde and retrograde transmission of syn 
have been observed in cell culture models [16; 52] the issue of directional bias in syn pathology 
transmission remains controversial [3; 17; 46]. Accordingly, we undertook the current study to 
investigate whether the longitudinal evolution of syn inclusions and direction of propagation 
can be predicted by directional trans-neuronal network transmission based on the anatomic 
network connectivity (or “connectome”) of the mouse. 
 Using the DNT model and mouse connectome, we studied propagation of syn 
inclusions from the olfactory bulb over time and analyzed the fitting of these predictions to our 
published in vivo data [34; 36]. Our work demonstrates that the model of propagation via 
neuronal networks fits the best with our published in vivo observations. Our work also confirms 
that a spatial diffusion model fits very poorly with our in vivo data. We also found that a 
retrograde spreading of inclusions during the first months after injection of syn fibrils followed 
by the involvement of anterograde progression explains with the pattern of inclusions 
propagation we observe after triggering synucleinopathy in the olfactory bulb. In addition, we 
applied our DNT model to two additional models of propagation: our dataset based on striatal 
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injections of PFFs [12] and a published dataset from a model of intra-nigral injection of alpha-
synuclein fibrils [25]. 
 
Methods 
 Our previously published work supported the idea that syn pathology propagates along 
axonal pathways, but we could only provide correlative evidence. Therefore, we further analyzed 
the propagation of syn-inclusions from the olfactory bulb in wild type mice. To this end, we 
developed a model of the theoretical pattern of propagation based on different propagation 
mechanisms (spatial proximity-based propagation by diffusion; connectivity-based propagation 
along fiber tracts in anterograde or retrograde directions). We implemented this theoretical 
model using published data on the mouse connectivity network and compared the fitting of our 
theoretical models to our in vivo observations.  
 
Mouse Brain Connectivity Network. We use data from the Allen Institute for Brain Science’s 
Mouse Connectivity Atlas (MCA) to create the mouse connectivity network. This network is 
derived from viral tracing studies and contains fully directional connectivity intensity 
information from 426 regions across both hemispheres; more information on the MCA can be 
found at the Allen Institute’s website and in the citation [28]. The network we use here can be 
obtained either on the Allen Institute’s website in the ‘Mouse Connectivity Atlas’ section or in 
Supplemental Materials attachment #4 from the above cited paper [28]. 
 
Mouse experiments and data collection for original synucleinopathy dataset (propagation of 
synucleinopathy from the olfactory bulb). We injected C57/Bl6 wild type mice unilaterally into 
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the olfactory bulb with syn pre-formed fibrils (PFFs) made of recombinant wild-type mouse 
syn PFFs (mPFFs) or wild-type human syn PFFs (huPFFs). The mice were sacrificed via 
transcardial perfusion with 4% paraformaldehyde in groups at either 1, 3, 6, 9, 12, or 18 months 
post-injection. The entire brains were sectioned coronally on a microtome into 30 µm thick 
sections in 8 series. Free-floating sections were stored in cryoprotectant until use. We stained 
every 8
th
 section of the entire brain with Ab51253 (Abcam) for syn phosphorylated on Serine 
129, a marker of pathological syn [2; 33; 34; 36]. Endogenous peroxidase were blocked by 
incubation with 3% H2O2 for 20 min. Sections were then blocked in 10% normal goat serum, 
0.3% triton x100, 0.4% Bovine serum albumin; followed by overnight incubation with rabbit anti 
pser129 antibody (1/10000 in 2% normal goat serum, 0.3% triton X100). We incubated the 
sections with secondary antibody goat anti-rabbit biotinylated (1:500, Vector lab) in blocking 
solution. Sections were then incubated for 1hour in ABC (ABC Kit, Vector lab) and revealed 
using DAB kit (Vector lab).  
These sections were blind coded nd were analyzed at x20 using Nikon eclipse Ni-U 
microscope. We semi-quantitatively rated syn inclusions on a 0-4 scale (one score per brain 
region) based on relative abundance of pser129 inclusions: 0=no aggregates; 1=sparse: very few 
neurites, max 1 soma; 2=mild inclusions; 3=dense inclusions; 4=very dense inclusions) for 4 
mice per group at 1 month post-injection, 4 mPFF and 3 huPFF injected mice at 3 months, 5 
mPFF and 4 huPFF injected mice at 6 months, 3 mPFF and 5 huPFF injected mice at 9 months, 7 
mPFF and 5 huPFF injected mice at 12 months, and 5 huPFF and 3 mPFF injected mice at 18 
months. Mouse brain regions were manually identified using the Paxinos and Franklin mouse 
brain atlas [29]. The list of the brain regions where syn inclusions were detected can be found 
in the original publications [34; 36]. Importantly, the staining conditions used would detect only 
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dense pser129-positive inclusions and we have shown previously [34; 36] that these inclusions 
shared the markers for pathological syn aggregates (colocalization with p62, ubiquitin and 
Thioflavin-S positive). During the scoring, any weak homogenously stained cell bodies were 
excluded from analysis to semi-quantify only dense inclusions.  
Further details on mouse experiment methodology for this data can be found in the same 
original publications [34; 36]. It should be noted that data from timepoints up to 12 months post-
injection [36] and the dataset obtained at 18 months post-injection [34] were quantified 
separately and some subregions were grouped differently. Thus, the datasets were not directly 
comparable, and so r, r, and p-values cannot be directly compared. Instead we observe that the 
pattern of results produced by comparing the 18-month dataset with our modeled predictions 
remains consistent with the suggested pattern of increasingly heavy involvement of anterograde 
transit along fiber tracts as a driver of syn inclusions propagation. We still include the 18-
month data with other quantified timepoints in Figure 5 as this is meant to be illustrative of the 
pattern of results we see. Our more in-depth analyses separate the data up to 12-months (Figures 
2 & 3) and at 18-months (Figure 4) post-injection into different figures. 
 
Mouse experiments and data collection for original dataset from intrastriatal injections of 
PFFs. For striatal injections, human alpha-synuclein was purified and assembled into PFFs in 
house following previously published protocols [23; 50]. PFFs were thawed and sonicated as 
previously published [34; 36]. 4 week old OF1-Swiss mice were injected stereotactically 2ul of 
PFFs unilaterally into the dorsal striatum as previously described (striatum coordinates from 
bregma: AP; +0.2mm, ML:-2.0mm, DV: -2.6mm). Mice were euthanized 8 weeks post injection 
by deep anesthesia with sodium pentobarbital and perfused transcardially with 0.9% saline, then 
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4% paraformaldehyde (PFA) in phosphate buffer. We collected the brains and post-fixed them 
for 24 hours in 4% PFA. Brains were then stored in 30% sucrose in phosphate buffer at 4 ˚C until 
use. Brains were sectioned coronally into 40 um thick sections on a freezing microtome. Free 
floated sections were stored in cryoprotectant. 
 The following staining protocol and semiquantitative analyses were employed: Pser129 
inclusions was semi-quantified across almost 40 regions, at one timepoint 8 weeks post-injection 
with in house recombinant human PFFs. The semi-quantification in this study was based on 
immunohistochemistry and followed the same procedure for converting IHC signal to semi-
quants as in [34; 36]. While this dataset is only cross-sectional rather than longitudinal, as it only 
contains one timepoint, it contains data from each individual mouse. With this dataset we 
accordingly assessed whether there was an identifiable directional predilection, according to our 
DNT modeling, in syn spread. The citation for this dataset can be found in [12]. 
 
Mouse synucleinopathy datasets obtained from other sources (intra-nigral injections of 
fibrils). To further investigate the propagation of abnormal inclusions in regards to theoretical 
propagation along axonal network, we chose to apply our connectivity model to another 
published dataset: Masuda-Suzukake, et al., 2013 [25]. Similar to our previous work [34; 36], 
this study used immunohistochemistry as the basis for all quantifications or semi-quantifications 
and wild-type mice. In the study by Masuda-Suzukake et al., [25] mice were injected into the 
substantia nigra with recombinant syn fibrils, and at least 40 separate brain regions were 
quantified for syn inclusions. The investigators semi-quantitatively assessed syn pathology by 
grading regional severity out to 15 months post-injection using 3 months and 6 months as 
intermediary timepoints.  
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Connectivity metrics, NT, and DNT. Connectivity metrics are calculated based on the topology 
of the mouse brain network derived from the MCA, where connectivity is represented as 
“outgoing” along the rows and “incoming” along the columns [28]. We generated a directed and 
weighted connectivity measure with seed regions by summing the weighted row-wise or column-
wise values in the MCA at the seed nodes. We could then correlate each selected region’s 
measured syn inclusions with its weighted connectivity, in both anterograde and retrograde 
directions, with the seed nodes in each study. Further information on using the MCA and its 
connectivity data for graph analyses can be found at the original citation [28] and in our prior 
paper using this atlas [26]. 
 NT and DNT modeling is similarly dependent on the MCA in this study, and on regional 
graph adjacency to the seed nodes or nodes already containing inclusions. We first calculate the 
Normalized Adjacency or Laplacian Matrix, L, given by the equation below: 
L = I – DR
-(1/2)
 · C · DC
-(1/2)
 
where C is the connectivity matrix from the MCA, I is the identity matrix, and DR and DC are the 
row and column wise diagonal matrices from the MCA. Previous graph theoretic work has 
characterized diffusion over a network from defined seed points and has been shown to be 
predictive for both volumetric loss [16; 30] and metabolic dysfunction [31] in patients with AD 
or other tauopathic dementia, as well as for mouse models of tauopathy and amyloidopathy [26; 
27]: 
XNT(t) = e
-βLt
 · X(0) (1) 
Here L is the Laplacian Matrix, βt is a constant representing diffusion time determined by when 
it maximizes R, which is the change in R-value from βt = 0 to maximum, X(0) is a vector with 
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n number of nodes length representing seeding, and X(t) is a vector with n number of nodes 
length representing the final pattern of network diffusion. Further information on the derivation 
of the above equation and graph diffusion modeling can be found at the aforementioned 
citations. 
 In the present study, we use a modified version of the above NT model equation so that 
we could both capture the directionality information from the MCA allowing us to represent 
synucleinopathy as not only a process of spread but also of accumulation, analogous to a prion-
like disorder. We captured the directionality information from the MCA by calculating different 
networks for each direction, where C represents the standard connectivity network, C
T
 represents 
the network in the retrograde direction, and the summed connectivity of both, C + C
T
, represents 
the undirected network derived from the MCA. Here we use an integrative or summative 
approach to capture accumulation and so the equation can be represented in two manners: 
XDNT(i) = e
-βLt
 · X(i-1) + X(i-1) (2) 
More information on the mathematics behind this approach can be found in our previous work 
[26; 27; 31]. The Spatial diffusion model (SPD) uses the same Laplacian and model equation, 
(2), from above; the difference between NT or DNT models and the SPD model is that the SPD 
model, as its network, instead utilizes the Cartesian distances, in voxels, between the centers of 
mass of any given region pair, rather than their axonal connectivity. 
 
Data analyses. All analyses performed were a variant of a standard linear regression using 
natural log transformed regressions due to empirical pathology and predicted values being best 
fit by exponential distributions. As in our previous studies [26; 27], we assessed each model by 
considering the Pearson’s R-statistic of the correlation between the (D)NT model, evaluated at 
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all model times t, and the empirical regional distribution of synucleinopathy concentration from 
the mouse brains. The model time t is not directly knowable form the model, and hence we 
chose to record the maximum correlation achieved by the model at all possible model times. We 
collected two quantities at the peak correlation: the Pearson R-value, as well as the R-value, 
here defined as the difference between the maximum R-value, and the R-value achieved by the 
model at t = 0, i.e. the synuclein inclusions seed pattern. The latter is a relevant measure of 
model performance, since it indicates how much additional value is added by network 
transmission beyond the initial seeding pattern. To determine directional bias, we subtracted 
retrograde DNT R-values from anterograde DNT R-values, as given by Eqn. (3): 
Bias =RANT  — RRET (3) 
A calculated bias value of 0 using Eqn. (3) would indicate no bias, a value >0 would indicate a 
bias in the anterograde direction, and a value <0 would indicate a bias in the retrograde direction. 
To test for the effects of progression time on directional bias in syn propagation we correlated 
each measured timepoint’s retrograde and anterograde bias, across all studies, and correlated that 
with the time of measurement (in months) after study initiation. We also correlated the bias 
difference scores, as calculated above, across timepoints. Because we present 24 total 
correlations, when assessing for significance, we corrected the -value threshold for 
significance, originally at p < 0.05, by dividing it by 24 to yield a significance cutoff at p < 
0.002. We analyzed the striatal injection dataset from [12] using two-sample t-tests to compare r-
values across all data using anterograde versus retrograde biased DNT. All statistical analyses 
were performed using MatLab unless explicitly stated otherwise. 
 
Results 
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To investigate the propagation of synucleinopathy throughout the brain and define in which 
direction trans-axonal propagation occurs, we compared the data collected in our in vivo model 
to the theoretical propagation pattern based on regular axonal transmission (NT), retrograde 
axonal transmission (DNT-ant), anterograde axonal transmission (DNT-ret) and Spatial 
Diffusion (SPD), as calculated using Equations 1, 2, evaluated on the (426 x 426) connectivity 
matrix obtained from the Allen Institute for Brain Science’s Mouse Connectivity Atlas (MCA). 
First, we aimed to go beyond the kind of correlative analysis of isolated or selected brain regions 
reported in previous studies, and instead wanted to create a model-based mathematical validation 
of the network transmission hypothesis on the entire brain netw rk. Second, we aimed to 
quantitatively establish whether directional bias is observed in serial inclusions data and can 
explain patterns of synucleinopathy propagation. Figures 1a & b illustrate directional spreading 
of inclusions and the DNT model, and Figure 1c shows parameter fitting across t-values using 
the DNT model, as well as predictive and non-predictive model curves. In Figure 1d, we provide 
an example of the anatomical illustrations we use with the DNT model, along with a universal 
legend for all such figure panels.  
 
Interregional -syn propagation initially mirrors retrograde direction spread along fiber 
tracts, but increasingly involves anterograde direction transit as time elapses. Using equation 
(2) and a seed signal placed at the injection site in the olfactory bulb, we evolved the DNT model 
at all model “diffusion times” t. We first selected 3 and 12 months as timepoints representing 
respectively short and long amounts of time post-injection, and then assessed interregional syn 
inclusions propagation. The peak R-value between the model evaluated at all model times t, and 
empirical regional syn inclusions data at 3 months post-injection, both retrograde DNT, R = 
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0.51, p < 0.01 and undirected NT, R = 0.44, p < 0.01, trend towards significantly matching the 
data of mice injected with mPFFs (Figure 2a-b). We anatomically illustrate the data and our 
retrograde DNT (DNT-Ret) model’s predictions in Figure 2c using a “glass brain” rendering 
whereby spheres represent brain regions and their size is proportional to the regional value of 
interest. Anterograde DNT (DNT-Ant) and Spatial diffusion (SPD) models do not significantly 
recreate empirical inclusion pattern at 3 months post-injection. However, by 12 months 
following syn fibrils injection, anterograde DNT, R = 0.63, p < 0.002, along with retrograde 
DNT, R = 0.60, p < 0.002, and undirected NT, R = 0.68, p < 0.002 (Figure 2d-e) all produce 
significant recreations of empirical regional syn inclusions data in mice injected with mPFFs. 
We anatomically illustrate our anterograde DNT model’s regional inclusions predictions and 
empirical data in Figure 2f. The SPD model continues to fail to produce any pattern that 
significantly matches empirical data. 
We observe a remarkably similar pattern in our datasets between injection at 3 and 12-
months post injection in mice injected with huPFFs. Retrograde DNT, R = 0.65, p < 0.002, and 
undirected NT, R = 0.59, p < 0.002 significantly recreate empirical regional syn inclusions 
patterns at 3-months post-injection, while anterograde DNT does not (Figure 3a-b). We 
anatomically illustrate the strong match between retrograde DNT and empirical data in Figure 
3c. However, by 12-months post-injection anterograde DNT, R = 0.72, p < 0.002, significantly, 
and most faithfully, recreates empirical regional patterns of syn inclusions (Figure 3d-e). 
Retrograde DNT, R = 0.57, p < 0.01, trends toward, and undirected NT, R = 0.67, p < 0.002 
significantly, recreate empirical inclusions patterns (Figure 3d-e). We anatomically illustrate the 
data and the anterograde DNT model’s recreation in Figure 3f. The SPD model does not recreate 
spatiotemporal syn inclusions patterns in mice injected with huPFFs.  
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We further analyzed the 18-month post-injection data and observed the same 
phenomenon of implied heavy involvement of anterograde direction fiber tract transit in mice 
injected with both mPFFs and huPFFs. As referred to in our note above, the R, R, and p-values 
at 18 months are not directly comparable with those from the other timepoints in our dataset, so 
we analyze and present the 18-months data separately. We found that anterograde DNT produces 
a significant, and the strongest, recreation of regional inclusions patterns in both mice injected 
with huPFFs, R = 0.64, p < 0.002 (Figure 4a-b) and mice injected with mPFFs, R = 0.70, p < 
0.002 (Figure 4d-e), compared to retrograde DNT, non-directional NT or spatial diffusion. Data 
at 18-months post-injection from both mice injected with huPFFs and mPFFs also trends towards 
or does produce significant, albeit not as faithful, recreations by retrograde DNT, R = 0.49, p < 
0.01 (huPFFs), R = 0.60, p < 0.002 (mPFFs), and undirected NT, R = 0.55, p < 0.01 (huPFFs), R 
= 0.63, p < 0.002 (mPFFs) (Figures 4a-b & 4d-e). We anatomically illustrate data as well as 
predictions from our anterograde and retrograde DNT models in Figure 4c (huPFFs) and Figure 
4f (mPFFs). We again find the consistent pattern, across injectate types, of implied heavy 
involvement of anterograde direction fiber tract travel as a driver of syn pathology spread.  
We next computed R-values as described in Data Analysis subsection of Methods. We 
repeated this for anterograde, retrograde and bidirectional DNT models, as well as the non-
network spatial diffusion model. We repeated above analysis by comparing the model against 
each individual time point of the empirical mouse data. We found that the DNT model of 
retrograde spread of syn along fiber tracts, as modeled by (DNT-Ret), fits better the in vivo 
syn propagation pattern, as measured by R-value against empirical syn inclusion data at 3, 6, 
and 9 months post-injection than does anterograde spread, modeled by (DNT-Ant.). However, by 
12 months (the last numerically directly comparable timepoint in these data – please refer to 
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material and methods), this pattern is reversed and anterograde DNT gives a better fit for 
spatiotemporal syn inclusions propagation. Furthermore, despite being slightly different in 
terms of number and location of regions quantified, the data obtained from 18-months post-
injection shows the best fits with modeled synucleinopathy spread proceeding in the anterograde, 
as opposed to retrograde, direction, consistent with the 12-months results. This result is 
consistent regardless of whether mice were initially injected with mouse- (Figure 5a) or human- 
(Figure 5b) PFFs. Furthermore, bias towards anterograde synucleinopathy propagation, as 
measured by anterograde DNT R-value minus retrograde DNT R-value, consistently increases 
over time in both human and mouse PFF datasets (Figure 5c).  
 
Data using other injection sites suggests a similar pattern of early retrograde and later 
anterograde spread involvement in interregional syn propagation. We first directly test 
whether there might be an initial retrograde bias in early post-injection syn inclusions, using the 
dataset obtained from the Masuda-Suzukake, et al., 2013 [25] publication and another dataset 
from one of our labs [12]. We find that in the dataset from [25], at both 3 and 6 months post-
injection, akin with similar timepoints post-injection from our own dataset (see above), there is a 
retrograde bias in how well DNT fits syn inclusions data. We further find that, in other data 
from one of our labs [12], the spatial pattern of syn inclusions at only 8 weeks post-injection 
with fibrils, is best fit by retrograde DNT, p < 0.002, (Figure 6a) using a two-sample t-test. Akin 
to results obtained using our own datasets, there is however a switch to a finding of anterograde 
bias in how well DNT fits syn pathology data by 15 months post-injection (Figure 6b). We 
subsequently used the data from [25], to create an example illustration of the phenomenon of 
implied heavy and increasing anterograde direction fiber tract transit involvement in 
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interregional syn propagation, as R-values for retrograde DNT are strong by 3 and 6-months 
post-injection, but anterograde DNT R-values are even higher than those of retrograde DNT by 
15 months post-injection (Figure 6c). We anatomically illustrate our results using data from the 
Masuda-Suzukake, et al., 2013, study in Figure 6d. More information on the dataset from [25] 
and the data from Patrik Brundin’s lab used here can be obtained in the Mouse synucleinopathy 
dataset obtained from published source subsection of the Methods section. These results and 
their implications are further explored in the Discussion.  
 
Discussion 
Our results confirm that syn inclusions are likely to spread along axons and 
transsynaptically after triggering synucleinopathy by localized injection of syn fibrils. We also 
observed that both anterograde and retrograde syn propagation are possible. Our results suggest 
that syn inclusions spreading is directionally biased with a predominance of retrograde 
propagation first, and that the directional bias of syn pathology propagation changes over time. 
Specifically, until 9 months post injection, a propagation model involving retrograde transport 
reproduces the pattern we observed in our animal experiments. In a second phase, 12 months 
post injection and later, a combination of retrograde and anterograde propagation explains the 
spatial pattern observed in vivo. A time-dependent directional bias can help explain why in 
human synucleinopathies some brain regions that are strongly connected to an affected brain area 
are spared early on, but not later, in the disease course.  
We found that our mathematical model of anatomical spreading of  syn inclusions 
applied well to both our own data from a mouse model involving syn PFFs injection into the 
olfactory bulb [34; 36], as well as in mice where syn fibrils or PFFs were injected into either 
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the Substantia nigra [25] or striatum [12]. While we consistently observed a preferred retrograde 
spread early and anterograde spread late after injection of fibrils/ PFFs, we do imply that the 
directional switch we find here is a general rule. It is possible that the particular conformation of 
the initial seed of syn aggregates (i.e. specific syn “strains”) and the anatomical region where 
the first seeding event takes place (e.g. olfactory bulb versus substantia nigra) will significantly 
influence the direction (antero- or retrograde) of spread. We discuss the relevance of this to both 
syn pathology in general and with regards to specific synucleinopathies (e.g. PD, DLB) in 
subsections below. 
 
Transsynaptic and fiber tract-based spread model re licates the syn inclusions spread 
observed in vivo. Axonal transport followed by transsynaptic spread have been proposed as the 
predominant mechanisms underlying syn pathology propagation between brain regions [1; 9; 
10; 11; 14; 33; 40; 45]. Some studies have utilized cell cultures models [17; 52] that do not 
reflect the complexity of brain connectivity and also lack several of its cellular components (e.g. 
different glia). Other researchers question the transsynaptic spread hypothesis entirely, arguing 
that the spread of syn pathology does not follow a synaptic connectivity rule [41; 42]. We 
explicitly test the transsynaptic and connectome based spread hypothesis using our current DNT 
model, with connectome data obtained from the Allen Brain Institute mesoscale mouse 
connectome [http://connectivity.brain-map.org; 28]. This atlas provides detailed anatomy of 426 
different nodes (corresponding to brain regions), and their connections are based on extensive 
tracing experiments. The connectome takes into account the direction of transport of the tracers 
and the weight of the different connections. It is, therefore, a very powerful tool to investigate 
the theoretical patterns of propagation based on anterograde, retrograde or diffuse spreading of 
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pathological seeds. To use this connectome with our DNT modeling, we had to make several 
assumptions. We assumed that there are no brain-region specific biases in the transfer or uptake 
of their adenovirus tracer [28] and that uptake is therefore even, allowing for some noise, across 
all parts of the mouse brain. We also assumed that there is a directly proportional relationship 
between fluorescent signal from the viral tracer and the total number or volume of axonal tracts 
from the seeded to the signal region. As discussed in the ABI paper introducing the MCA [28], 
these assumptions are unlikely to be true across the board, but are likely accurate enough at the 
coarse parcellation of a brain into 426 regions. Importantly, making these assumptions allows 
our model to simulate spread over the entire connectome.  
We demonstrate clear correspondence between regions most likely (based on neuronal 
connections) to exhibit pathology from the region where the initial seeding takes place (the 
olfactory bulb, substantia nigra, or striatum) and the regions that we found to contain syn 
inclusions in in vivo experiments [25; 34; 36] (Figures 2-5). To confirm that the fitting of the 
theoretical propagation pattern with the empirical in vivo data is not dependent on site of 
pathology-initiation, we analyzed previously published datasets using two different injection 
sites [25; 34; 36]. We found the same correspondence between our theoretical modeling of 
propagation and published data from [25] using with the substantia as initiation site. We further 
demonstrate retrograde DNT recreates spatial syn patterns [12] (Fig 6d). We also tested 
whether a pattern of spread based on spatial, rather than connectome proximity to the seed 
region, would recapitulate syn patterns, implying potential active or passive extracellular 
spread of pathogenic protein aggregates. This analysis showed that spatial diffusion is not a 
predictor of syn inclusions localization in the two datasets we examined (Figures 2-6), and 
provides further support for the transsynaptic syn pathology spread hypothesis. 
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Importantly, recently published work from Virginia L.Y. Lee’s group investigated also 
the spread of syn pathology through the mouse brain using connectome modeling [22]. In this 
study, the authors investigated the propagation of syn inclusions from several injection sites in 
a time window of 1 to 6 months post injection. In this study, inclusions were also detected with 
an antibody directed against hyperphosphoraylated alpha-synuclein and stained sections were 
analyzed quantitatively in an automated way. The authors also implemented in their model the 
expression level of syn at the injection site. Despite different methods used, both our work and 
Henderson et al.’s demonstrate that early propagation is occurring preferentially in a retrograde 
direction, and that the preferential retrograde propagation is a generalized mechanism to all the 
brain regions each lab tested. In addition, the authors observed that the regional level of 
expression of syn influences strongly the vulnerability of a given brain region to develop syn 
inclusions. The study by Henderson et al explores only short injection delays (up to 6 months), 
and thus do not investigate the long delays post injections where we observed a switch to a 
preferential anterograde propagation direction after 9 months, both in our OB-injection dataset 
and in data from [25].  
 
Directional switching of syn propagation might explain divergent spatiotemporal pathology 
development patterns between patients. One advantage of our paradigm is the possibility to test 
transregional spread along fiber tracts in both anterograde (pre-to-postsynaptic) and retrograde 
(post-to-presynaptic) directions. Interestingly, we found that both anterograde and retrograde 
directions can successfully recreate transregional syn inclusions spread, consistent with prior 
cell culture [17; 52] and in vivo [38; 47; 48] studies showing both anterograde and retrograde 
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transport of syn. In fact, our results suggest that the directional bias of syn spread may in fact 
change over time. 
 What cellular mechanisms might contribute to change biases in directional spread over 
time? Prior work on transsynaptic syn propagation suggests that spread through a neural 
network in an anterograde direction might involve release of exosomes into the synaptic cleft 
[40]. However, retrograde spread can also occur, via release into the synaptic cleft from 
dendrites or soma, and possibly enter the presynaptic side via tunneling nanotubes or even 
receptor mediated internalization [45]. For network spread to occur bidirectionally, both 
transsynaptic propagation and axonal transport/diffusion of syn must be bidirectional, 
assumptions that are supported by cell culture and microfluidic studies [39; 43; 49]. 
Interestingly, syn can interfere with the net directionality of axonal transport by its interaction 
with kinesin and dynein motors [39; 49], and thereby affect directional bias.    
We speculate that biased spread influences spatiotemporal development of syn 
pathology and partly explains why some regions exhibit syn inclusions while others do not. The 
enteric nervous system and / or the olfactory system represent two possible locations where the 
accumulation of misfolded syn species overwhelm the cellular protein degradation mechanisms 
in PD and DLB. In PD, syn inclusions development in the central nervous system is generally 
first observed in dorsal motor nucleus of the vagus nerve (the origin of enteric nerves) and in 
olfactory areas such as the olfactory bulb and anterior olfactory nucleus [4; 5; 6; 7; 8; 15; 37; 
45]. In DLB, syn aggregates are frequently seen in olfactory structures as well as limbic system 
[2].  
Our work posits not only directional biases in syn spread, but a directional switch in 
these biases (Figures 2-6). Syn can interact with both anterograde direction kinesin and 
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retrograde direction dynein axonal transport protein families [3]. Importantly, syn misfolding 
appears to decrease its anterograde transport by kinesin proteins, and increase its retrograde 
transport by dynein proteins [51] by at latest 8 weeks post-aggregation initiation. This could 
explain an early retrograde bias in syn propagation that shifts to either bidirectional or 
anterograde syn spread as syn inclusions progress. Because both the substantia nigra and 
olfactory areas have dense connections with the striatum [28], the relative sparsity of syn 
aggregates in the striatum in PD might be viewed as unexpected. However, if transsynaptic syn 
spread is predominantly in the retrograde direction early in disease course (Figures 2-6), we 
would indeed not expect early pronounced syn inclusions accumulation in the striatum because 
most of the connections between the injected olfactory bulb and the striatum are afferents to the 
striatum [28].  
 
Assumptions and limitations. There are limitations of our model and of our datasets. First, our 
DNT modeling rely on several assumptions so we could model the spread over the entire 
connectome (we assumed that the uptake of adenovirus tracer is even in the brain, and assume 
that the tracers fluorescent signal is proportional to the volume of axonal tracts containing 
fluorescent signal). As mentioned earlier and as discussed in previous work [28], our 
assumptions are likely accurate enough for the parcellation in 426 brain regions we are using 
here.   
In addition, the model does not consider region-specific factors that may influence the 
susceptibility of regions to become ‘infected’ by pathogenic syn. Therefore, our model does not 
consider region-specific factors which can influence an area’s susceptibility to develop 
inclusions, regardless of spread, a concern other recent work investigating syn inclusion spread 
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notes [22]. Our model also does not reflect that neurons might die, due to aggregates forming, in 
some brain regions, and therefore neither updates the connectome to account for loss of white 
matter nor updates the model to account for loss of syn that dead neurons once contained. 
Uneven antibody penetrance between mice could potentially confound data. There are also 
limitations regarding our dataset because it is only semi-quantitative [34; 36]. However, in our 
long-term study [34], we performed densitometry analysis of pser129 inclusions on a restricted 
number of brain regions, in addition to our semi-quantitative analysis, and the results from both 
method were consistent indicating that our semi-quantitative analysis using scores reflects well 
the density of inclusions present in a given brain region. Finally, cellular inflammatory and 
excocytosis responses that occur in response to injection with -synuclein fibrils could affect 
spread processes for -synuclein inclusions at timepoints closest to injection. The fit of the DNT 
model at 3-months post-injection is worse than at any other timepoint, potentially indicating 
injection-response cellular processes as a limitation for how well a spread or diffusion model can 
fit data at timepoints close to injection. 
Additionally of note, some technical aspects differs between the different datasets. We 
performed injections into the olfactory bulb in 7-8 weeks old C57/Bl6 mice, while Masuda-
Suzukake and coworkers [25] injected older mice of the same strains. Regarding our intrastriatal 
injections, we injected 4 week-old mice of a different background strain (OF1mice). The fibrils 
used for each dataset were different or produced by different labs: for olfactory bulb injections, 
mPFFs and huPFFs were produced by K. Luk while huPFFs used for striatal injections were 
produced in our lab (following K Luk’s published protocol) [50]; and Masuda-Suzukake’s fibrils 
were produced following a different protocol in their own lab [25]. Thus, it is possible that these 
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different assemblies have different seeding and propagation capacities. Despite these differences, 
our results demonstrate similar propagation characteristics in the three different datasets. 
 
Concluding remarks. In conclusion, we provide evidence that the propagation of 
synucleinopathy in fibril-injection mouse models occurs via neural network and 
transsynaptically. Our findings in mice support the hypothesis by Braak and colleagues of 
propagation of syn pathology via neuronal networks in humans [4; 5; 6; 7; 8; 15]. In addition, 
we demonstrate that the preferred direction of syn inclusions propagation is initially retrograde, 
and becomes anterograde at several months post injection, indicating that the preferred direction 
can switch over time.  
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Figure legends 
Figure 1. Anatomical example of network transmission, what the DNT model represents, and 
how to assess it. (a) α-Syn fibrils can be internalized both in the dendrite/cell body compartment 
and in axons. α-Syn fibrils are actively transported along microtubules both in the anterograde 
(driven by kinesin) and retrograde (driven by dynein) direction, perhaps directly in 
the cytoplasm or perhaps in transport vesicles following endocytosis. Aggregation is thought to 
initially occur in axons, where α-syn fibrils can encounter and template the misfolding of soluble 
endogenous α-syn proteins that are transported along axons for delivery to synapses. Figure 
adapted with permission from Bieri, et al., 2018. (b) Graphic illustration of the whole brain 
directional connectivity network, with nodes representing brain regions, and connection strengths 
{Cij} representing tracer-derived mesoscale connectivity. Examples of anterograde and 
retrograde transmission on this network are depicted. This macroscopic network transmission 
model is driven by the cellular-level transmission and transport processes depicted in panel A. 
(c) Example of a βt-curve showing r-value across βt parameter values for predictive (peak at βt > 
0) and non-predictive models (peak at βt = 0). (d) A color legend and brain showing the color 
scheme, by major region, for all the balls depicting regions in all anatomical illustrations of 
mouse brains throughout the rest of the paper. The dot sizes correspond to randomly generated 
“example“ or “pseudo“ inclusions amounts, per-region, where each dot represents one region in 
its center of mass. In anatomic illustrations of this nature with actual results, the inclusions 
amounts will not be random, but will rather be determined by inclusions severity recorded from 
data or predicted by a given NT model. 
Figure 2. Synuclein inclusion spread is better modeled by retrograde DNT at early timepoints, 
and anterograde DNT at later timepoints. (a) βt-curve showing NT models’ r-value with mPFF 
data at 3-months post-injection at different diffusion time constants. (b) Scatterplot of the NT 
models at their peak β-diffusion time constant, as in (a) to the left, versus data. (c) Anatomical 
illustrations of mPFF synuclein inclusion data and DNT-retrograde simulation. (d) βt-curve 
showing NT models’ r-value with mPFF data at 12-months post-injection at different diffusion 
time constants. (e) Scatterplot of the NT models at their peak β-diffusion time constant, as in (d) 
to the left, versus data. (f) Anatomical illustrations of mPFF induced synuclein inclusions at 12 
months post injection and the corresponding anterograde-DNT simulation. AMY = amygdala, 
AOB = accessory olfactory bulb, AON = anterior olfactory nucleus, DG = dentate gyrus, ENT = 
entorhinal cortex, MOB = main olfactory bulb, PIR = piriform cortex, SUB = subiculum, TT = 
tenia tecta. Please see Figure 1 for color legend for the major region color scheme of the balls 
denoting regional syn inclusions. The red arrow points toward the MOB where the PFFs were 
injected. Significance level: + p < 0.01, * p < 0.02 
Figure 3. Synuclein inclusion spread is better modeled by retrograde DNT at early timepoints, 
and anterograde DNT at later timepoints. (a) βt-curve showing NT models’ r-value with huPFF 
data at 3-months post-injection at different diffusion time constants. (b) Scatterplot of the NT 
models at their peak β-diffusion time constant, as in (a) to the left, versus data. (c) Anatomical 
illustrations of huPFF synuclein inclusion data and DNT-retrograde simulation. (d) βt-curve 
showing NT models’ r-value with huPFF data at 12-months post-injection at different diffusion 
time constants. (e) Scatterplot of the NT models at their peak β-diffusion time constant, as in (d) 
to the left, versus data. (f) Anatomical illustrations of huPFF induced synuclein inclusions at 12 
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months post injection and the corresponding anterograde-DNT simulation. All data and NT 
simulation values are log-transformed prior to both statistics and anatomical visualizations. 
AMY = amygdala, AOB = accessory olfactory bulb, AON = anterior olfactory nucleus, DG = 
dentate gyrus, ENT = entorhinal cortex, MOB = main olfactory bulb, PIR = piriform cortex, 
SUB = subiculum, TT = tenia tecta. Please see Figure 1 for color legend for the major region 
color scheme of the balls denoting regional syn inclusions. The red arrow points toward the 
MOB where the PFFs were injected. + p < 0.01, * p < 0.02 
 
Figure 4. At 18-months post injection, we find the same phenomenon of strong inclusion pattern 
recreation by our anterograde DNT model at timepoints far from injection, and in contrast with 
findings at earlier measured timepoints. (a) βt-curve showing NT models’ r-value with huPFF 
data at 18-months post-injection at different diffusion time constants. (b) Scatterplots for each 
model’s prediction at the βt diffusion rate constant that maximizes r-values with regional syn 
inclusion data from huPFF injected mice. (c) An anatomical illustration of regional syn 
inclusion pattern data and anterograde and retrograde DNT model predictions for huPFF injected 
mice. (d) βt-curve showing NT models’ r-value with mPFF data at 18-months post-injection at 
different diffusion time constants. (e) Scatterplots for each model’s prediction at the βt diffusion 
rate constant that maximizes r-values with regional syn inclusion data from mPFF injected 
mice. (f) An anatomical illustration of regional syn inclusion pattern data and anterograde and 
retrograde DNT model predictions for mPFF injected mice. AMY = amygdala, AOB = accessory 
olfactory bulb, AON = anterior olfactory nucleus, DG = dentate gyrus, ENT = entorhinal cortex, 
MOB = main olfactory bulb, NAcc = nucleus accumbens, PIR = piriform cortex, SUB = 
subiculum, TT = tenia tecta. Please see Figure 1 for color legend for the major region color 
scheme of the balls denoting regional syn inclusions. The red arrow points toward the MOB 
where the PFFs were injected. + p < 0.01, * p < 0.02 
Figure 5. DNT retrograde models are better predictors of synuclein inclusions closer to initial 
pathological injection, but anterograde DNT is a better predictor of synuclein inclusions as more 
time elapses following injection. (a) mPFF synuclein injected mice and (b) huPFF synuclein 
injected mice both show spatiotemporal synucleinopathy development such that at times closer 
to the initial injection, retrograde DNT is the best predictor, but at times farther from the 
injection, anterograde DNT better recapitulates syn inclusion spread than does retrograde DNT. 
(c) Calculated directional bias in the fit with data between anterograde and retrograde DNT 
models shifts towards anterograde DNT over time. A reference line at 0, the value at which there 
should be no directional bias, is added to the plot in (c). All data and NT simulation values are 
log-transformed prior to running statistics. 
Figure 6. Datasets using other injection sites show the same directional shift as our data: that at 
timepoints surrounding the injection, synuclein inclusions are better explained by a model 
positing retrograde spread, but at timepoints farther form the injection, models using anterograde 
spread perform better. (a) Another dataset from Patrik Brundin’s lab [12] using mice injected 
with fibrils into the striatum with regional quantification at 8-weeks post injection show the same 
pattern, regardless of genotype, as this early post-injection quantification of syn inclusions is 
best fit by retrograde DNT.  The next panels (b,c, d) use data from [24]: (b) Anterograde bias, 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 33 
calculated as in the y-axis legend above is strongest at 15-months post injection, implying that 
anterograde DNT, relative to retrograde DNT, performs better at later timepoints, across both 
ours and the Masuda-Suzukake, et al. 2013 study. A reference line at 0, the value at which there 
should be no directional bias, is added to the plot in (b). (c) An example, from Masuda-
Suzukake, et al., 2013, showing the same switch from synuclein inclusions being best recreated 
by retrograde DNT at early timepoints, to being best recapitulated by anterograde DNT at later 
timepoints. (d) An anatomic illustration of the data and DNT simulated data from Masuda-
Suzukake, et al. 2013, as in (b) & (c) above. All data and NT simulation values are log-
transformed prior to running correlations. + p < 0.01, * p < 0.02 
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Highlights 
 Mathematically modeling syn spread along fiber tracts recreates inclusions patterns 
 Modeled retrograde (post-to-presynaptic) spread best recreates early inclusions patterns 
 Modeled anterograde (pre-to-postsynaptic) spread better fits later inclusions pattern 
 Overall results indicate a potential directional switch in syn spread over time 
 All above results are consistent across multiple, independently collected, datasets 
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